Last ¥1,267 JPY
Change Today +18.00 / 1.44%
Volume 2.2M
4506 On Other Exchanges
As of 2:00 AM 07/31/14 All times are local (Market data is delayed by at least 15 minutes).

sumitomo dainippon pharma co (4506) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/10/14 - ¥1,947
52 Week Low
05/27/14 - ¥1,095
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SUMITOMO DAINIPPON PHARMA CO (4506)

Related News

No related news articles were found.

sumitomo dainippon pharma co (4506) Related Businessweek News

No Related Businessweek News Found

sumitomo dainippon pharma co (4506) Details

Sumitomo Dainippon Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients, food additives, veterinary medicines, diagnostics, and others in Japan, China, North America, and internationally. The company offers various pharmaceutical products, including therapeutic agents for hypertension, angina pectoris, arrhythmia, Parkinson’s disease, systemic fungal infections, and hepatocellular carcinoma; atypical antipsychotics; antidepressants; rapid-acting insulin secretagogues; vasodilators; and biguanide oral hypoglycemic drugs. It also provides products for various therapeutic indications, such as Anderson-Fabry disease, anti-hypertension, gastroprokines, carbapenem antibiotics, sedative hypnotics, short-acting and long-acting beta-agonist, inhaled corticosteroid, corticosteroid nasal spray, and serotonin-agonist antianxiety drug. In addition, the company offers ingredients and additives, which comprise polysaccharides, seasonings, and sweeteners; and chemical product materials consisting of cosmetic materials, active pharmaceutical ingredients, electronic chemicals, and coating materials. Further, it offers veterinary medicines for companion animals, including dogs and cats; and farm animals, such as cattle, swine, horses, and cultured fish. Additionally, the company develops point-of-care testing diagnostic products for infectious diseases; in-vitro diagnostics for bone and calcium metabolism, and central nervous system disorders; research materials that facilitate research related to medical care; and BBI-608 and BBI-503 anticancer drug candidates. It has a joint development agreement with Healios K.K. to develop iPS cell-derived retinal pigment epithelial cells for the treatment of age-related macular degeneration and other eye diseases. The company was formerly known as Dainippon Sumitomo Pharma Co., Ltd. and changed its name to Sumitomo Dainippon Pharma Co., Ltd. in June 2014. The company was founded in 1897 and is headquartered in Osaka, Japan.

7,015 Employees
Last Reported Date: 06/19/14
Founded in 1897

sumitomo dainippon pharma co (4506) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

sumitomo dainippon pharma co (4506) Key Developments

Dainippon Sumitomo Pharma Co., Ltd. to Report Q1, 2015 Results on Jul 30, 2014

Dainippon Sumitomo Pharma Co., Ltd. announced that they will report Q1, 2015 results on Jul 30, 2014

Dainippon Sumitomo Pharma Co., Ltd., Q1 2015 Earnings Call, Jul 30, 2014

Dainippon Sumitomo Pharma Co., Ltd., Q1 2015 Earnings Call, Jul 30, 2014

Dainippon Sumitomo Pharma Co., Ltd. has Changed its Name to Sumitomo Dainippon Pharma Co., Ltd

Dainippon Sumitomo Pharma Co., Ltd. changed its name to Sumitomo Dainippon Pharma Co., Ltd.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4506:JP ¥1,267.00 JPY +18.00

4506 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Albany Molecular Research Inc $19.37 USD +0.01
Eli Lilly & Co $62.62 USD -0.15
FUJIFILM Holdings Corp ¥2,969 JPY -22.50
GlaxoSmithKline Consumer Nigeria PLC 65.01 NGN -1.09
Vanda Pharmaceuticals Inc $14.74 USD +0.63
View Industry Companies

Industry Analysis


Industry Average

Valuation 4506 Industry Range
Price/Earnings 24.9x
Price/Sales 1.3x
Price/Book 1.3x
Price/Cash Flow 14.5x
TEV/Sales 0.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUMITOMO DAINIPPON PHARMA CO, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at